Cameron Turtle, Director, Chief Executive Officer, on August 03, 2026, sold 15,000 shares in Spyre Therapeutics (SYRE) for $1,432,705. Following the Form 4 filing with the SEC, Turtle has control over a total of 567,540 common shares of the company, with 567,540 shares held directly.
SEC Filing: